[ad_1]
-
Nanobiotix (NASDAQ: NBTX) shares gained more than 200% on Friday trading after it entered into final contract negotiations with a major global pharmaceutical company.
-
In its Q4 earnings release, Nanobiotix raised going concerns.
-
The company noted net losses of €57.0 million in 2022 and a net decrease in cash and cash equivalents of €42.5 million in 2022.
-
Nanobiotix stock is gaining on heavy volume, with a session volume of 30.262 million shares traded.
-
The company agreed to a non-binding term sheet for developing and commercializing lead nanotherapeutic candidate NBTXR3 with an undisclosed pharmaceutical company.
-
The arrangement is subject to negotiation and execution of a definitive agreement and each party’s requisite internal corporate approvals for the definitive terms.
-
Nanobiotix does not intend to make additional statements regarding negotiations unless and until it is appropriate to do so or a final definitive agreement has been signed.
-
Price Action: NBTX shares are up 244.8% at $7.00 on the last check Friday.
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Nanobiotix Stock Triples In Trading Session: What’s Going On With Stock On Friday originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source link
